Sama Therapeutics

Sama Therapeutics is a biotechnology and digital health company that develops precision neuropsychiatry solutions through its proprietary software-as-a-medical-device platform, iMAGiNE™. The platform integrates generative AI, computational neuroscience, and predictive analytics to analyze the transdiagnostic efficacy of pharmaceutical and neurostimulation treatments. By utilizing deep phenotyping, causal inference, digital twins, and multi-omics data—including neural, physiological, and behavioral phenotypes—the company aims to facilitate precision clinical trials and preclinical translation. This technology is designed to address a range of conditions, including cognitive, affective, interoceptive, and substance use disorders, by synthesizing and validating predictive biomarkers.

The company’s technology serves healthcare providers, clinical researchers, and patients by providing personalized brain health assessments and actionable clinical insights. By enabling more targeted therapeutic approaches, Sama Therapeutics seeks to improve the speed and accuracy of mental health and neurological care. Founded in 2022 and headquartered in Cambridge, Massachusetts, the company focuses on advancing integrative neurotechnology to unlock better outcomes for patients struggling with complex brain health indications. Through its interdisciplinary research, it seeks to optimize the translation of neuroscientific discovery into clinical practice.